Lixisenatide official document review · version 1
This page preserves this version's findings, scope and source pins. Open the current profile →
Inside the official reviews
Reviewed 2026-09-19 · Preserved version 1
The initial assessment focused on glucose control
EMA’s November 2012 review found HbA1c improvements when lixisenatide was added to specified background therapies. Placebo-adjusted changes and changes from baseline differed, and results varied between trial populations. EMA PDF pp. 77, 79 ↗
More findings, study links and document coverage
A comparison did not robustly establish equivalence
EMA judged noninferiority to exenatide on glycemic and weight outcomes not robustly demonstrated. A favorable overall regulatory decision did not mean every comparative endpoint was established. EMA PDF pp. 79 ↗
Safety interpretation needs the background regimen
The review identifies gastrointestinal symptoms, injection-site and allergic reactions, with hypoglycemia principally alongside insulin or sulfonylureas. Evidence in people over 75 and those with substantial kidney impairment was limited. EMA PDF pp. 77, 78, 79 ↗
Keep the historical review separate from later status
ELIXA was still ongoing in this assessment. The downloaded PDF is now marked as a product no longer authorized, so its original favorable recommendation is not proof of current EU authorization or later cardiovascular benefit. EMA PDF pp. 1, 80 ↗
Read the separate U.S. label account → Label version and indication scope are preserved there; these agency reviews describe their own dated evidence.
Document coverage
Selected sections read in 1 of 1 inventoried documents; 0 not yet reviewed. Reading selected sections does not establish complete appraisal of a document.
One selected official document from the retained EMA document inventory or an independently retrieved FDA application package. Other formulations, later variations, national records and the wider source inventory remain outside this reading. EMA inventory source ↗
Inspect documents, application identities and source pins
Page references use one-based PDF file pages, which can differ from printed page numbers. Candidate feed associations are not verified application identities.
Lyxumia : EPAR - Public assessment report ↗
Selected sections reviewed · ema-28007 · Document/feed date: 2026-02-05
Application identity and document date were checked in the PDF, independently of the URL year or candidate feed association.
Verified: Lyxumia · EMEA/H/C/002445 · Document dated 2012-11-28. Identity checked on PDF pp. 1.
Selected identity, clinical-summary and benefit-risk sections only; this is not a full-document or all-indication appraisal.
Retrieved 2026-09-19. Read PDF pages: 1, 77, 78, 79, 80 of 81. SHA-256:
bb64000d8ce3d69605a1b93466e94e1f08615da94f32e7f6c684f8a1853e4922.Feed-listed application (not a verified association): EMEA/H/C/002445.
Remaining work
- Review ELIXA results separately from the original glucose-control program.
- Verify the withdrawal history and current jurisdiction-specific products without inferring a safety cause from the withdrawal watermark.